Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42. https://doi.org/10.1001/jamaoncol.2017.0589.

Article  PubMed  PubMed Central  Google Scholar 

Sultana Q, Kar J, Verma A, Sanghvi S, Kaka N, Patel N, et al. A comprehensive review on neuroendocrine neoplasms: presentation, pathophysiology and management. J Clin Med. 2023;12:5138. https://doi.org/10.3390/jcm12155138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Associazione Italiana di Oncologia Medica (AIOM). Linee guida per la diagnosi e il trattamento delle neoplasie neuroendocrine(Rapporto n. 311). 2021. https://www.iss.it/documents/20126/8403839/LG-311-Neoplasie-Neuroendocrine_agg2022

American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S20-S42. https://doi.org/10.2337/dc24-S002.

Vergès B, Cariou B. mTOR inhibitors and diabetes. Diabetes Res Clin Pract. 2015;110:101–8. https://doi.org/10.1016/j.diabres.2015.09.014.

Article  CAS  PubMed  Google Scholar 

Gallo M, Ruggeri RM, Muscogiuri G, Pizza G, Faggiano A, Colao A. Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any? Cancer Treat Rev. 2018;67:1–9. https://doi.org/10.1016/j.ctrv.2018.04.013.

Article  PubMed  Google Scholar 

Natalicchio A, Faggiano A, Zatelli MC, Argentiero A, D’Oronzo S, Marrano N, et al. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol. 2022;169:103572. https://doi.org/10.1016/j.critrevonc.2021.103572.

Article  PubMed  Google Scholar 

Vitale G, Gaudenzi G, Oldani M, Pandozzi C, Filice A, Jaafar S, et al. Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group. Rev Endocr Metab Disord. 2024. https://doi.org/10.1007/s11154-024-09937-2.

Article  PubMed  Google Scholar 

Kusne YN, Kosiorek HE, Buras MR, Verona PM, Coppola KE, Rone KA, et al. Implications of neuroendocrine tumor and diabetes mellitus on patient outcomes and care: a matched case–control study. Future Sci OA. 2021;7. https://doi.org/10.2144/fsoa-2020-0190.

Resmini E, Minuto F, Colao A, Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol. 2009;46:85–95. https://doi.org/10.1007/s00592-009-0112-9.

Article  CAS  PubMed  Google Scholar 

Halfdanarson TR, Bamlet WR, McWilliams RR, Hobday TJ, Burch PA, Rabe KG, et al. Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study. Pancreas. 2014;43:1219–22. https://doi.org/10.1097/MPA.0000000000000234.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feola T, Puliani G, Sesti F, Modica R, Centello R, Minotta R, et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J Endocrinol Invest. 2022;45:849–57. https://doi.org/10.1007/s40618-021-01715-0.

Article  CAS  PubMed  Google Scholar 

Haugvik S-P, Hedenström P, Korsæth E, Valente R, Hayes A, Siuka D, et al. Diabetes, smoking, alcohol use, and family history of cancer as risk factors for pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Neuroendocrinology. 2015;101:133–42. https://doi.org/10.1159/000375164.

Article  CAS  PubMed  Google Scholar 

Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2016;27:68–81. https://doi.org/10.1093/annonc/mdv505.

Article  CAS  PubMed  Google Scholar 

Natalicchio A, Marrano N, Montagnani M, Gallo M, Faggiano A, Zatelli M, et al. Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view. J Endocrinol Invest. 2024. https://doi.org/10.1007/s40618-024-02417-z.

Article  PubMed  PubMed Central  Google Scholar 

Vernieri C, Casola S, Foiani M, Pietrantonio F, de Braud F, Longo V. Targeting cancer metabolism: dietary and pharmacologic interventions. Cancer Discov. 2016;6:1315–33. https://doi.org/10.1158/2159-8290.CD-16-0615.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Capurso G, Falconi M, Panzuto F, Rinzivillo M, Boninsegna L, Bettini R, et al. Risk factors for sporadic pancreatic endocrine tumors. Am J Gastroenterol. 2009;104:3034–41. https://doi.org/10.1038/ajg.2009.466.

Article  CAS  PubMed  Google Scholar 

Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, et al. Metformin use is associated with longer progression-free survival of patients with diabetes and pancreatic neuroendocrine tumors receiving everolimus and/or somatostatin analogues. Gastroenterology. 2018;155:479-489.e7. https://doi.org/10.1053/j.gastro.2018.04.010.

Article  CAS  PubMed  Google Scholar 

Garg SK, Shah VN. Newer therapies for diabetes management. Diabetes Technol Ther. 2014;16(Suppl 1):S119–27. https://doi.org/10.1089/dia.2014.1514.

Article  PubMed  Google Scholar 

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2021;46:101102. https://doi.org/10.1016/j.molmet.2020.101102.

Article  CAS  PubMed  Google Scholar 

Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3–14. https://doi.org/10.1016/j.molmet.2018.09.009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145:2653–9. https://doi.org/10.1210/en.2004-0015.

Article  CAS  PubMed  Google Scholar 

Marrano N, Biondi G, Cignarelli A, Perrini S, Laviola L, Giorgino F, et al. Functional loss of pancreatic islets in type 2 diabetes: How can we halt it? Metabolism. 2020;110:154304. https://doi.org/10.1016/j.metabol.2020.154304.

Article  CAS  PubMed  Google Scholar 

Bugliani M, Syed F, Paula FMM, Omar BA, Suleiman M, Mossuto S, et al. DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes. Mol Cell Endocrinol. 2018;473:186–93. https://doi.org/10.1016/j.mce.2018.01.019.

Article  CAS  PubMed  Google Scholar 

Drucker DJ. Glucagon-like peptide-1 and the Islet β-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology. 2003;144:5145–8. https://doi.org/10.1210/en.2003-1147.

Article  CAS  PubMed  Google Scholar 

Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia. 1999;42:856–64. https://doi.org/10.1007/s001250051238.

Article  CAS  PubMed  Google Scholar 

Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–6. https://doi.org/10.2337/diabetes.48.12.2270.

Article  CAS  PubMed  Google Scholar 

Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, Glucose-Intolerant Rats. Endocrinology. 2000;141:4600–5. https://doi.org/10.1210/endo.141.12.7806.

Article  CAS  PubMed  Google Scholar 

Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in zucker diabetic rats. Endocrinology. 2002;143:4397–408. https://doi.org/10.1210/en.2002-220405.

Article  CAS